Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 7/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12559619 | 0.83 | CYP11B1 (0.41) | CYP11B1CYP11B2CYP1A2PKMCYP19A1 | |
| SCHEMBL12559608 | 0.77 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP1A2PKMCYP19A1 | |
| SCHEMBL12559727 | 0.75 | CYP1A2 (0.38) | CYP11B1CYP11B2CYP1A2PKMSRD5A1 | |
| SCHEMBL14779528 | 0.74 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP1A2PKMCYP19A1 | |
| SCHEMBL22958360 | 0.74 | CYP11B1 (0.40) | CYP11B1CYP11B2CYP1A2PKMCYP19A1 | |
| SCHEMBL9378752 | 0.73 | CYP11B1 (0.52) | CYP11B1CYP11B2CYP1A2PKMCYP19A1 | |
| SCHEMBL20938817 | 0.72 | TP53 (0.37) | CYP11B1CYP11B2CYP1A2PKMAHR | |
| SCHEMBL428384 | 0.71 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP1A2PKMCYP19A1 | |
| SCHEMBL15463659 | 0.71 | CYP11B1 (0.37) | CYP11B1CYP11B2CYP1A2CYP19A1SRD5A1 | |
| SCHEMBL7278086 | 0.70 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP1A2PKMCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-RE48059-E1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-20190117648-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20170368060-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9839637-B1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-12 | — | — | US | disclosed |
| US-9839637-B1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-12 | — | — | US | disclosed |
| US-20130158044-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-8349840-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8349840-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-06-23 | — | — | US | disclosed |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-06-23 | — | — | US | disclosed |
| US-7888362-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-15 | — | — | US | disclosed |
| US-7888362-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-15 | — | — | US | disclosed |
| EP-1869025-B1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMA CO LTD (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368060-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | CYP11B1 226/4885CYP11B2 212/4885CYP1A2 38/4885 |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | GRIN2C, TPH1, HTR2C | CYP11B1 226/4885CYP11B2 212/4885CYP1A2 38/4885 |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | CYP11B1 226/4885CYP11B2 212/4885CYP1A2 38/4885 |
| US-20190117648-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | CYP11B1 226/4885CYP11B2 212/4885CYP1A2 38/4885 |
| US-20130158044-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | CYP11B1 226/4885CYP11B2 212/4885CYP1A2 38/4885 |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | CYP11B1 226/4885CYP11B2 212/4885CYP1A2 38/4885 |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | CYP11B1 226/4885CYP11B2 212/4885CYP1A2 38/4885 |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | CYP11B1 226/4885CYP11B2 212/4885CYP1A2 38/4885 |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | CYP11B1 226/4885CYP11B2 212/4885CYP1A2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.